Malondialdehyde in benign prostate hypertrophy: a useful marker?

Benign prostate hypertrophy (BPH) is the most common benign tumor in men due to obstruction of the urethra and, finally, uremia. Malondialdehyde (MDA) is a product derived from peroxidation of polyunsaturated fatty acids and related esters. Evaluation of MDA in serum represents a non-invasive biomar...

Descripción completa

Detalles Bibliográficos
Autores principales: Merendino, Rosaria Alba, Salvo, Francesco, Saija, Antonella, Di Pasquale, Giuseppe, Tomaino, Antonio, Minciullo, Paola Lucia, Fraccica, Giuseppe, Gangemi, Sebastiano
Formato: Texto
Lenguaje:English
Publicado: 2003
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781597/
https://www.ncbi.nlm.nih.gov/pubmed/12775364
http://dx.doi.org/10.1080/0962935031000097745
Descripción
Sumario:Benign prostate hypertrophy (BPH) is the most common benign tumor in men due to obstruction of the urethra and, finally, uremia. Malondialdehyde (MDA) is a product derived from peroxidation of polyunsaturated fatty acids and related esters. Evaluation of MDA in serum represents a non-invasive biomarker of oxidative stress. Prostate-specific antigen (PSA) is a sensitive marker for prostatic hypertrophy and cancer. We analyzed MDA serum levels to evaluate the oxidative stress in BPH. To this end, 22 BPH patients and 22 healthy donors were enrolled. Data show an increase of MDA level in BPH patients and a positive correlation between PSA and MDA levels. In conclusion, we describe a previously unknown relationship between PSA and MDA as an index of inflammation and oxidative stress in BPH.

Ejemplares similares